Skip to main content

Advertisement

SpringerLink
Log in

LncRNA DDX11-AS1: a novel oncogene in human cancer

  • Review Article
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

Long noncoding RNA (lncRNA) is a newly identified type of noncoding RNA with a length of more than 200 nucleotides. The latest research shows that lncRNAs play important roles in the occurrence and development of human tumours by acting both as carcinogenic genes and as tumour suppressor genes. LncRNAs plays a role in various biological processes, such as cell growth, apoptosis, migration and invasion. The newly discovered lncRNA DDX11-AS1 is abnormally highly expressed in various malignant tumours, such as hepatocellular carcinoma, colorectal cancer, osteosarcoma, bladder cancer, NSCLC and gastric cancer. DDX11-AS1 mainly regulates the expression of related genes through direct or indirect ways to perform its functions in carcinogenicity. These results indicate that DDX11-AS1 may be a marker or therapeutic target of tumours. This review summarizes the biological function and mechanism of DDX11-AS1 in the process of tumour development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data availability

Not available.

Abbreviations

LncRNA:

Long noncoding RNA

DDX11-AS1:

DDX11 antisense RNA 1

EZH2:

Enhancer of zeste 2 polycomb repressive complex 2 subunit

DNMT1:

DNA methyltransferase 1

LATS2:

Large tumour suppressor, homologue 2

CLDN7:

Claudin 7

LAMB3:

Laminin subunit beta3

CDK6:

Cyclin-dependent kinase 6

SPC18:

Signalling point code 18

IRS1:

Recombinant insulin receptor substrate 1

PI3K:

Phosphatidylinositol 3-kinase

AKT/PKB:

Protein kinase B

AFP:

Alpha-fetoprotein

HCC:

Hepatocellular carcinoma

CRC:

Colorectal cancer

GC:

Gastric cancer

NSCLC:

Non-small cell lung cancer

BC:

Bladder cancer

EMT:

Epithelial-mesenchymal transition

Bcl-2:

B-cell lymphoma-2

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.

    Article  PubMed  Google Scholar 

  2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.

    Article  PubMed  Google Scholar 

  3. Veneziano D, Di Bella S, Nigita G, Lagana A, Ferro A, Croce CM. Noncoding RNA: current deep sequencing data analysis approaches and challenges. Hum Mutat. 2016;37:1283–98.

    Article  CAS  PubMed  Google Scholar 

  4. Theis M, Paszkowski-Rogacz M, Weisswange I, Chakraborty D, Buchholz F. Targeting human long noncoding transcripts by endoribonuclease-prepared siRNAs. J Biomol Screen. 2015;20:1018–26.

    Article  CAS  PubMed  Google Scholar 

  5. Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al. Landscape of transcription in human cells. Nature. 2012;489:101–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lee JT. Epigenetic regulation by long noncoding RNAs. Science. 2012;338:1435–9.

    Article  CAS  PubMed  Google Scholar 

  7. Zhu S, Li W, Liu J, Chen CH, Liao Q, Xu P, Xu H, Xiao T, Cao Z, Peng J, et al. Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR-Cas9 library. Nat Biotechnol. 2016;34:1279–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Zhu J, Kong F, Xing L, Jin Z, Li Z. Prognostic and clinicopathological value of long noncoding RNA XIST in cancer. Clin Chim Acta. 2018;479:43–7.

    Article  CAS  PubMed  Google Scholar 

  9. Han P, Li JW, Zhang BM, Lv JC, Li YM, Gu XY, Yu ZW, Jia YH, Bai XF, Li L, et al. The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/beta-catenin signaling. Mol Cancer. 2017;16:9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Li P, Ruan X, Yang L, Kiesewetter K, Zhao Y, Luo H, Chen Y, Gucek M, Zhu J, Cao H. A liver-enriched long non-coding RNA, lncLSTR, regulates systemic lipid metabolism in mice. Cell Metab. 2015;21:455–67.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Dang Y, Lan F, Ouyang X, Wang K, Lin Y, Yu Y, Wang L, Wang Y, Huang Q. Expression and clinical significance of long non-coding RNA HNF1A-AS1 in human gastric cancer. World J Surg Oncol. 2015;13:302.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Vance KW, Sansom SN, Lee S, Chalei V, Kong L, Cooper SE, Oliver PL, Ponting CP. The long non-coding RNA Paupar regulates the expression of both local and distal genes. EMBO J. 2014;33:296–311.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Lu D, Luo P, Wang Q, Ye Y, Wang B. lncRNA PVT1 in cancer: a review and meta-analysis. Clin Chim Acta. 2017;474:1–7.

    Article  CAS  PubMed  Google Scholar 

  14. Zhang H, Zhu JK. Emerging roles of RNA processing factors in regulating long non-coding RNAs. RNA Biol. 2014;11:793–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. St Laurent G, Wahlestedt C, Kapranov P. The Landscape of long noncoding RNA classification. Trends Genet. 2015;31:239–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Hadji F, Boulanger MC, Guay SP, Gaudreault N, Amellah S, Mkannez G, Bouchareb R, Marchand JT, Nsaibia MJ, Guauque-Olarte S, et al. Altered DNA methylation of long noncoding RNA H19 in calcific aortic valve disease promotes mineralization by silencing NOTCH1. Circulation. 2016;134:1848–62.

    Article  CAS  PubMed  Google Scholar 

  17. Wu R, Su Y, Wu H, Dai Y, Zhao M, Lu Q. Characters, functions and clinical perspectives of long non-coding RNAs. Mol Genet Genom. 2016;291:1013–33.

    Article  CAS  Google Scholar 

  18. Zhou M, Zhang XY, Yu X. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma. Biomed Pharmacother. 2017;85:348–54.

    Article  CAS  PubMed  Google Scholar 

  19. Akhade VS, Dighe SN, Kataruka S, Rao MR. Mechanism of Wnt signaling induced down regulation of mrhl long non-coding RNA in mouse spermatogonial cells. Nucleic Acids Res. 2016;44:387–401.

    Article  CAS  PubMed  Google Scholar 

  20. Tsang FH, Au SL, Wei L, Fan DN, Lee JM, Wong CC, Ng IO, Wong CM. Long non-coding RNA HOTTIP is frequently up-regulated in hepatocellular carcinoma and is targeted by tumour suppressive miR-125b. Liver Int. 2015;35:1597–606.

    Article  CAS  PubMed  Google Scholar 

  21. Zhang P, Cao L, Fan P, Mei Y, Wu M. LncRNA-MIF, a c-Myc-activated long non-coding RNA, suppresses glycolysis by promoting Fbxw7-mediated c-Myc degradation. EMBO Rep. 2016;17:1204–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Lopez-Pajares V. Long non-coding RNA regulation of gene expression during differentiation. Pflugers Arch. 2016;468:971–81.

    Article  CAS  PubMed  Google Scholar 

  23. Song J, Ahn C, Chun CH, Jin EJ. A long non-coding RNA, GAS5, plays a critical role in the regulation of miR-21 during osteoarthritis. J Orthop Res. 2014;32:1628–35.

    Article  CAS  PubMed  Google Scholar 

  24. Li J, Tian H, Yang J, Gong Z. Long noncoding RNAs regulate cell growth, proliferation, and apoptosis. DNA Cell Biol. 2016;35:459–70.

    Article  CAS  PubMed  Google Scholar 

  25. Wu Y, Liu H, Shi X, Yao Y, Yang W, Song Y. The long non-coding RNA HNF1A-AS1 regulates proliferation and metastasis in lung adenocarcinoma. Oncotarget. 2015;6:9160–72.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Cai B, Ma W, Bi C, Yang F, Zhang L, Han Z, Huang Q, Ding F, Li Y, Yan G, et al. Long noncoding RNA H19 mediates melatonin inhibition of premature senescence of c-kit(+) cardiac progenitor cells by promoting miR-675. J Pineal Res. 2016;61:82–95.

    Article  CAS  PubMed  Google Scholar 

  27. Rao A, Rajkumar T, Mani S. Perspectives of long non-coding RNAs in cancer. Mol Biol Rep. 2017;44:203–18.

    Article  CAS  PubMed  Google Scholar 

  28. Malik B, Feng FY. Long noncoding RNAs in prostate cancer: overview and clinical implications. Asian J Androl. 2016;18:568–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Shi M, Zhang XY, Yu H, Xiang SH, Xu L, Wei J, Wu Q, Jia R, Wang YG, Lu XJ. DDX11-AS1 as potential therapy targets for human hepatocellular carcinoma. Oncotarget. 2017;8:44195–202.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Li Y, Zhuang W, Huang M, Li X. Long noncoding RNA DDX11-AS1 epigenetically represses LATS2 by interacting with EZH2 and DNMT1 in hepatocellular carcinoma. Biochem Biophys Res Commun. 2019;514:1051–7.

    Article  CAS  PubMed  Google Scholar 

  31. Zhang H, Lin J, Chen J, Gu W, Mao Y, Wang H, Zhang Y, Liu W. DDX11-AS1 contributes to osteosarcoma progression via stabilizing DDX11. Life Sci. 2020;254:117392.

    Article  CAS  PubMed  Google Scholar 

  32. Chen D, Chen J, Gao J, Zhang Y, Ma Y, Wei W, Wei Y. LncRNA DDX11-AS1 promotes bladder cancer occurrence via protecting LAMB3 from downregulation by sponging miR-2355-5p. Cancer Biother Radiopharm. 2020;5:319–28.

    Article  CAS  Google Scholar 

  33. Li Q, Wang S, Wu Z, Liu Y. DDX11-AS1exacerbates bladder cancer progression by enhancing CDK6 expression via suppressing miR-499b-5p. Biomed Pharmacother. 2020;127:110164.

    Article  CAS  PubMed  Google Scholar 

  34. Ren Z, Liu X, Si Y, Yang D. Long non-coding RNA DDX11-AS1 facilitates gastric cancer progression by regulating miR-873-5p/SPC18 axis. Artif Cells Nanomed Biotechnol. 2020;48:572–83.

    Article  CAS  PubMed  Google Scholar 

  35. Song W, Qian Y, Zhang MH, Wang H, Wen X, Yang XZ, Dai WJ. The long non-coding RNA DDX11-AS1 facilitates cell progression and oxaliplatin resistance via regulating miR-326/IRS1 axis in gastric cancer. Eur Rev Med Pharmacol Sci. 2020;24:3049–61.

    CAS  PubMed  Google Scholar 

  36. Liu H, Zhang Z, Wu N, Guo H, Zhang H, Fan D, Nie Y, Liu Y. Integrative analysis of dysregulated lncrna-associated ceRNA network reveals functional lncRNAs in gastric cancer. Genes (Basel). 2018;9:303.

    Article  CAS  Google Scholar 

  37. Feng X, Yang S, Zhou S, Deng S, Xie Y. Long non-coding RNA DDX11-AS1 promotes non-small cell lung cancer development via regulating PI3K/AKT signalling. Clin Exp Pharmacol Physiol. 2020. https://doi.org/10.1111/1440-1681.13325.

    Article  PubMed  Google Scholar 

  38. Liao HT, Huang JW, Lan T, Wang JJ, Zhu B, Yuan KF, Zeng Y. Identification of the aberrantly expressed LncRNAs in hepatocellular carcinoma: a bioinformatics analysis based on RNA-sequencing. Sci Rep. 2018;8:5395.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  39. Tian JB, Cao L, Dong GL. Long noncoding RNA DDX11-AS1 induced by YY1 accelerates colorectal cancer progression through targeting miR-873/CLDN7 axis. Eur Rev Med Pharmacol Sci. 2019;23:5714–29.

    PubMed  Google Scholar 

  40. George J, Patel T. Noncoding RNA as therapeutic targets for hepatocellular carcinoma. Semin Liver Dis. 2015;35:63–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Huang JL, Zheng L, Hu YW, Wang Q. Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis. 2014;35:507–14.

    Article  CAS  PubMed  Google Scholar 

  42. Invernizzi F, Vigano M, Grossi G, Lampertico P. The prognosis and management of inactive HBV carriers. Liver Int. 2016;36(Suppl 1):100–4.

    Article  CAS  PubMed  Google Scholar 

  43. Favoriti P, Carbone G, Greco M, Pirozzi F, Pirozzi RE, Corcione F. Worldwide burden of colorectal cancer: a review. Updates Surg. 2016;68:7–11.

    Article  PubMed  Google Scholar 

  44. Kong J, Sun W, Li C, Wan L, Wang S, Wu Y, Xu E, Zhang H, Lai M. Long non-coding RNA LINC01133 inhibits epithelial-mesenchymal transition and metastasis in colorectal cancer by interacting with SRSF6. Cancer Lett. 2016;380:476–84.

    Article  CAS  PubMed  Google Scholar 

  45. Zhou Y, Chen S, Cheng S, Wei Q, Fathy AH, Shan T. The prognostic value of high LncRNA AFAP1-AS1 expression in various cancers: a systematic review and meta-analysis containing 21 studies. Clin Chim Acta. 2018;481:147–53.

    Article  CAS  PubMed  Google Scholar 

  46. Gong J, Cui Z, Li L, Ma Q, Wang Q, Gao Y, Sun H. MicroRNA-25 promotes gastric cancer proliferation, invasion, and migration by directly targeting F-box and WD-40 Domain Protein 7, FBXW7. Tumour Biol. 2015;36:7831–40.

    Article  CAS  PubMed  Google Scholar 

  47. Li Z, Yu X, Wang Y, Shen J, Wu WK, Liang J, Feng F. By downregulating TIAM1 expression, microRNA-329 suppresses gastric cancer invasion and growth. Oncotarget. 2015;6:17559–69.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Gong Y, Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. World J Gastroenterol. 2015;21:2949–58.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Li Z, Lei H, Luo M, Wang Y, Dong L, Ma Y, Liu C, Song W, Wang F, Zhang J, et al. DNA methylation downregulated mir-10b acts as a tumor suppressor in gastric cancer. Gastric Cancer. 2015;18:43–544.

    Article  CAS  PubMed  Google Scholar 

  50. Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer. World J Gastroenterol. 2016;22:4812–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Wang W, Shen XB, Jia W, Huang DB, Wang Y, Pan YY. The p53/miR-193a/EGFR feedback loop function as a driving force for non-small cell lung carcinoma tumorigenesis. Ther Adv Med Oncol. 2019;11:1758835919850665.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. Szpechcinski A, Florczuk M, Duk K, Zdral A, Rudzinski S, Bryl M, Czyzewicz G, Rudzinski P, Kupis W, Wojda E, et al. The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients. Cell Mol Life Sci. 2019;76:3641–56.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Osmani L, Askin F, Gabrielson E, Li QK. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy. Semin Cancer Biol. 2018;52:103–9.

    Article  CAS  PubMed  Google Scholar 

  54. Wang Y, Li Y, He H, Wang F. Circular RNA circ-PRMT5 facilitates non-small cell lung cancer proliferation through upregulating EZH2 via sponging miR-377/382/498. Gene. 2019;720:144099.

    Article  CAS  PubMed  Google Scholar 

  55. Pottgen C, Eberhardt W, Stamatis G, Stuschke M. Definitive radiochemotherapy versus surgery within multimodality treatment in stage III non-small cell lung cancer (NSCLC): a cumulative meta-analysis of the randomized evidence. Oncotarget. 2017;8:41670–8.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Kang DH, Kim JO, Jung SS, Park HS, Chung C, Park D, Lee JE. Efficacy of vinorelbine monotherapy as third- or further-line therapy in patients with advanced non-small-cell lung cancer. Oncology. 2019;97:356–64.

    Article  CAS  PubMed  Google Scholar 

  57. Ploeg M, Aben KK, Kiemeney LA. The present and future burden of urinary bladder cancer in the world. World J Urol. 2009;27:289–93.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, et al. Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol. 2018;74:784–95.

    Article  PubMed  Google Scholar 

  59. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–5.

    Article  PubMed  Google Scholar 

  60. Chen J, Wang L, Tang Y, Gong G, Liu L, Chen M, Chen Z, Cui Y, Li C, Cheng X, et al. Maspin enhances cisplatin chemosensitivity in bladder cancer T24 and 5637 cells and correlates with prognosis of muscle-invasive bladder cancer patients receiving cisplatin based neoadjuvant chemotherapy. J Exp Clin Cancer Res. 2016;35:2.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  61. Fernandez-Gomez J, Madero R, Solsona E, Unda M, Martinez-Pineiro L, Gonzalez M, Portillo J, Ojea A, Pertusa C, Rodriguez-Molina J, et al. Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model. J Urol. 2009;182:2195–203.

    Article  PubMed  Google Scholar 

  62. Hollenbeck BK, Dunn RL, Ye Z, Hollingsworth JM, Lee CT, Birkmeyer JD. Racial differences in treatment and outcomes among patients with early stage bladder cancer. Cancer. 2010;116:50–6.

    Article  PubMed  Google Scholar 

  63. Molina JR, Quevedo JF, Furth AF, Richardson RL, Zincke H, Burch PA. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer. 2007;110:2434–40.

    Article  PubMed  Google Scholar 

  64. Cepeda MLA, Sosa AJ, Mora G. Telangiectatic osteosarcoma in an infant. Bol Med Hosp Infant Mex. 2017;74:60–4.

    PubMed  Google Scholar 

  65. Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–43.

    Article  PubMed  Google Scholar 

  66. Savage SA, Mirabello L. Using epidemiology and genomics to understand osteosarcoma etiology. Sarcoma. 2011;2011:548151.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Yu W, Tang L, Lin F, Yao Y, Shen Z, Zhou X. High-intensity focused ultrasound: noninvasive treatment for local unresectable recurrence of osteosarcoma. Surg Oncol. 2015;24:9–15.

    Article  PubMed  Google Scholar 

  68. Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M. Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000;18:4016–27.

    Article  CAS  PubMed  Google Scholar 

  69. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.

    Article  PubMed  Google Scholar 

  70. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2009;152:3–13.

    Article  PubMed  Google Scholar 

  71. Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44:547–53.

    Google Scholar 

Download references

Funding

This work was supported by the Anhui Science and Technology Major Project (No 17030801020) and the Chen Feihu Central Support for Local-Provincial Translational Medicine Project in 2017 (2017zhyx31).

Author information

Author notes

  1. Yubin Feng and Maomao Wu contributed equally to this work.

Authors and Affiliations

  1. Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, School of Pharmacy, Anhui Medical University, Hefei, 230032, Anhui Province, China

    Yubin Feng, Shuang Hu, Xiaoqing Peng & Feihu Chen

  2. The Key Laboratory of Anti‐inflammatory and Immune medicines, Ministry of Education, Hefei, Anhui, China

    Yubin Feng, Shuang Hu, Xiaoqing Peng & Feihu Chen

  3. Department of Pharmacy, Anhui Chest Hospital, Hefei, Anhui Province, China

    Maomao Wu

Authors
  1. Yubin Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Maomao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shuang Hu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xiaoqing Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Feihu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

FYB planned and conducted the experiments, analysed the data and wrote the text. WMM conducted the experiments and analysed the data. HS participated in the design of the experiment and contributed to discussing the data and text. PXQ and CFH conceived the study, participated in its design and coordination as well as providing critical review of the manuscript. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Xiaoqing Peng or Feihu Chen.

Ethics declarations

Conflict of interest

The authors declare that they have no competing interests.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Feng, Y., Wu, M., Hu, S. et al. LncRNA DDX11-AS1: a novel oncogene in human cancer. Human Cell 33, 946–953 (2020). https://doi.org/10.1007/s13577-020-00409-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-020-00409-8

Keywords

Search

Navigation